| Name | Title | Contact Details |
|---|
Precision AQ is a global life science commercialization vendor that specializes in Health Economics and Outcomes Research (HEOR), pricing, and market access consulting for pharmaceutical and biotech companies. Headquartered in New York City, the company operates with a strong emphasis on remote work. Precision AQ is dedicated to transforming patient lives by improving access to life-changing therapies through innovative strategies and data-driven approaches. The company offers a wide range of services to support clients throughout the healthcare journey. These include research, strategy, and product development, as well as marketing, branding, and public relations. Precision AQ also focuses on generating evidence for HEOR, optimizing payer access, and facilitating investor relations. Their expertise helps clients navigate the complexities of the market and enhance their presence among healthcare professionals and patients.
PaulHood goes beyond basic tax preparation. We nurture all aspects of financial health, offering peace of mind and proactive solutions tailored to your unique individual and business needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Introba is one of the worlds largest building engineering and consulting firms with more than 1,000 employees in offices across the United States, Canada, the United Kingdom, Serbia, and Australia. Committed to reshaping the world, our problem solvers combine cutting-edge digital solutions with emerging innovations and industry-leading sustainability strategies to transform the built environment. We collaborate with our clients to create living systems that are smart, secure, resilient, and connected – spaces that uplift communities, protect the health of the planet, and adapt to meet the demands of the future.